Empirical Financial Services LLC d.b.a. Empirical Wealth Management Has $737,000 Holdings in Astrazeneca Plc $AZN

Empirical Financial Services LLC d.b.a. Empirical Wealth Management decreased its holdings in Astrazeneca Plc (NYSE:AZN) by 60.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,739 shares of the company’s stock after selling 5,800 shares during the quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Astrazeneca were worth $737,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. Triumph Capital Management bought a new stake in shares of Astrazeneca in the 3rd quarter valued at about $25,000. MV Capital Management Inc. bought a new stake in Astrazeneca in the fourth quarter valued at approximately $26,000. Mascoma Wealth Management LLC acquired a new stake in Astrazeneca during the 1st quarter valued at approximately $26,000. Bangor Savings Bank increased its position in Astrazeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after purchasing an additional 154 shares during the period. Finally, Eagle Bay Advisors LLC bought a new position in Astrazeneca during the 4th quarter worth approximately $30,000. 20.35% of the stock is owned by institutional investors.

Astrazeneca Stock Up 0.4%

Astrazeneca stock opened at $169.08 on Friday. The firm has a market capitalization of $262.23 billion, a price-to-earnings ratio of 25.39, a price-to-earnings-growth ratio of 1.37 and a beta of 0.24. The firm’s fifty day moving average price is $182.44 and its two-hundred day moving average price is $188.47. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The company had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. On average, equities research analysts predict that Astrazeneca Plc will post 10.26 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on AZN. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. Finally, HSBC downgraded Astrazeneca from a “buy” rating to a “hold” rating in a report on Monday. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Astrazeneca has a consensus rating of “Moderate Buy” and a consensus target price of $211.00.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.